Dice Therapeuticsincis A Biopharmaceutical Company Focused On Developing Innovative Oral Medicines For Chronic Autoimmune And Inflammatory Diseasesnow A Wholly Owned Subsidiary Of Eli Lilly And Companydice Leverages Its Proprietary Delscape Technology Platform To Create Novel Oral Therapeutic Candidates Targeting Biologically Validated Pathways In Immunology The Company Specializes In Designing And Developing Small Molecule Drugswith Its Lead Program Targeting The Il 17 Cytokinewhich Plays A Role In Conditions Like Psoriasisdice S Pipeline Includes A Range Of Oral Therapeutic Candidates Aimed At Improving Treatment Options For Autoimmune And Inflammatory Diseasesthe Acquisition By Eli Lilly Enhances Lilly S Immunology Portfoliointegrating Dice S Promising Drug Candidates Into Its Offerings
